SP- 01A : A New Oral HIV Entry Inhibitor
Mar 2, 2005 - 2:24:00 PM
|
|
|
Samaritan believes SP-01A cripples HIV's ability to enter cells by blocking the proteins on Human T Cells that would, otherwise, facilitate HIV's entry into those cells.
|
By Akanksha, Pharmacology Correspondent,
[RxPG] Samaritan Pharmaceuticals Inc.,a developer of innovative drugs announced today it is rapidly progressing with its PII/III study of SP-01A, a new kind of pill that, Samaritan believes, blocks the AIDS virus before it ever enters the human cell.
Four sites have been selected to conduct Samaritan's trial for HIV-infected patients experiencing resistance to antiretroviral therapy.
In addition, Internal Review Boards responsible for protecting study patients have almost completed their reviews; the Principal Investigators, the Central Lab and Study Monitors are all in place, along with the Study Director, with all anticipating the start of the study.
Dr. Janet Greeson, CEO of Samaritan stated, "When you think about who we are competing against to win, companies like Pfizer, GlaxoSmithKline, Schering-Plough, and being headquarted in Vegas, it makes you feel as though we are playing Texas Hold-em against Big Pharma. If you can imagine, we are holding pocket deuces and they're holding pocket aces, pocket kings, and big slick; none of us know what the flop is going to be and that is the way it is with study trials. Of course, we know we are the underdog but we see the flop as deuce, deuce and an ace and have the perseverance to win; who knows, maybe we will be the next million dollar baby."
Samaritan believes SP-01A cripples HIV's ability to enter cells by blocking the proteins on Human T Cells that would, otherwise, facilitate HIV's entry into those cells.
It is estimated that some 78% of HIV patients are resistant to at least one of the four classes of HIV drugs; and 50% are resistant to at least two classes. In addition, 10-20% of newly infected patients already have resistance to one or more HIV Drugs.
Publication:
Samaritan Pharmaceuticals Inc.
On the web:
Samaritan 
|
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to AIDS Newsletter
|
|
|
|
Additional information about the news article
|
Samaritan, a small Biopharmaceutical company and against all odds, is committed to winning the race to approval for its life-saving affordable drugs. Samaritan, in collaboration with Georgetown University, is advancing its proprietary compounds for AIDS, Alzheimer's, Cancer and Cardiovascular disease. Samaritan's HIV oral, entry inhibitor, drug is projected to enter PII/III clinical trials in 2005.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
